Accedi a banche dati online | Convegnodetail
mail
Anteprima di stampa
 
 

4th Annual Chronic Kidney Disease Drug Development Summit (CKD)

Evvnt Promotion / evvnt
-
01.03.2022 - 03.03.2022  Hyatt Regency Boston, 1 Avenue de Lafayette, 02111 Boston, USA
Time: 08:00 - 17:00
 
Temi della conferenza
As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting.
Professional congress organizer (PCO)
Hanson Wade
Annotazioni
Speakers: Agnes Benardeau Senior Director, Head of Cardio-Renal Biology, Novo Nordisk, Alan Glicklich, Chief Medical Officer, Chinook Therapeutics, Alan Yu, Professor and Kidney Institute Director, University of Kansas Medical Center and more.
 

Informazioni ed Iscrizioni:

https://go.evvnt.com/915880-2?pid=4832
Mr. Jessica Durston
 
Categorie
Medicina General
Lingua
Inglese
Quote del Congresso
USD 2099.0 - USD 4996.0
I partecipanti attesi
1000
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."

Österreichisches Rotes KreuzEuropean Health Forum GasteinnewTreeCenter of ExcellenceAMREF - African Medical and Research FoundationAlumni Club Medizinische Universität WienÄrztekammer für WienEuropean Public Health Association (EUPHA)